In patients with psoriatic arthritis (PsA), methotrexate is the most commonly used first-line conventional synthetic disease-modifying antirheumatic drug (csDMARD), and it is included in all major treatment guidelines.
Despite wide use in clinical practice, methotrexate is not approved for the treatment of PsA in the United States and many other countries. Furthermore, data on the effectiveness of combining csDMARDs (including methotrexate) with anti-TNF agents remain conflicting.
Dr Saakshi Khattri of Mount Sinai discusses the role of such combination therapy in the treatment of patients with PsA.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Combination Therapy in Psoriatic Arthritis - Medscape - May 27, 2020.
Comments